U.S. state attorneys general will meet Justice Department attorneys next week to share information on their investigations into Alphabet's Google, Reuters' Nandita Bose write, citing two sources familiar with the matter. The probes revolve around monopolistic behavior that may harm consumers through Google's control of online advertising markets and search traffic, the report notes. Reference Link

NantHealth has announced Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer patients during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology. NantHealth's presentation utilized data on whole exome DNA tumor and paired germline and matched deep whole transcriptomic sequencing to identify a higher percentage of CRC patients with HER2 signaling than conventional methods of immunohistochemistry or fluorescence in-situ hybridization. ERBB2 gene expression was evaluated using NantOmics Nant50 gene classifier, which separates patients into subgroups that have been well established in breast cancer. The application of this tool to colorectal cancer proved surprising with greater than expected HER2 positive patients with a normally expected distribution of CMS classification. This finding suggests a possible utility for this tool in a new clinical setting. In addition, the HER2 enriched group did not show differentially expressed mutations in other targetable genes such as PIK3CA and BRAF, highlighting the potential importance of HER2 targeting in this population.

NantHealth has announced new real-world data on treatment patterns for patients with advanced colorectal cancer during a poster session at the 2020 Gastrointestinal Cancer Symposium sponsored by the American Society of Clinical Oncology. NantHealth's presentation examined therapeutic preferences and treatment patterns among advanced CRC patients using data from NantHealth's Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform. Detailed information from 6,325 treatment plans was analyzed to identify treatment patterns using regorafenib and trifluridine + tipiracil for advanced CRC patients as third-line of therapy. National Comprehensive Cancer Network guidelines state that regorafenib and trifluridine+tipiracil are both treatment options for patients who have progressed through all available regimens. Across all 6,325 treatment plans submitted for this patient population, regorafenib or trifluridine+tipiracil was the submitted treatment in 361 of the treatment plans, making them the 9th and 13th most frequently requested drugs in this setting. While the total number of treatment plans for regorafenib was higher than that for trifluridine+tipiracil, the submission of trifluridine+tipiracil has increased over time, consistent with the latter drug's more recent introduction into the market.

The new Boeing (BA) 777X jetliner took to the skies on Saturday, entering the next phase of its test program. Based on the 777 and with proven technologies from the 787 Dreamliner, the 777X took off in front of thousands at Paine Field in Everett, Washington, at 10:09 a.m. local time for a three-hour, 51-minute flight over Washington state before landing at Seattle's Boeing Field. The first of four dedicated 777-9 flight test airplanes, WH001 will now undergo checks before resuming testing in the coming days. The test fleet, which began ground testing in Everett last year, will endure a comprehensive series of tests and conditions on the ground and in the air over the coming months to demonstrate the safety and reliability of the design. The newest member of Boeing's market-leading widebody family, the 777X will deliver 10% lower fuel use and emissions and 10% lower operating costs than the competition through advanced aerodynamics, the latest generation carbon-fiber composite wing and the most advanced commercial engine ever built, GE (GE) Aviation's GE9X. Boeing expects to deliver the first 777X in 2021. The program has won 340 orders and commitments from carriers around the world, including ANA, British Airways, Cathay Pacific Airways, Emirates, Etihad Airways, Lufthansa, Qatar Airways and Singapore Airlines.